Subclinical cardiac dysfunction in cancer patients: A case report
DOI:
https://doi.org/10.24265/horizmed.2020.v20n1.12Keywords:
Cardio-oncology, Cardiotoxicity, Anthracyclines, Trastuzumab, Cardiac strain, Troponin IAbstract
Cardiotoxicity is a relatively new clinical entity which, in the case of heart failure, is a marker of poor prognosis in cancer survivors who have received more frequent treatments with anthracyclines or trastuzumab. In these patients, detecting a cardiac dysfunction in the subclinical stage can reveal early myocardial involvement and avoid further damage to the heart. Technological advances in imaging, such as the global longitudinal strain, and the increase in troponin I enable the detection of this condition. This case report involves a 17-year-old female patient who was diagnosed with osteosarcoma in her left leg and received anthracyclines. In the cardiovascular evaluation, she was asymptomatic, and showed normal left ventricular function (60 %), decreased strain rate (-15 %) and elevated troponin I levels (115 ng/mL). Asymptomatic cardiac dysfunction was diagnosed and carvedilol 6.25 mg/day was prescribed. After 3 months of treatment, the strain rate (-20 %) and troponin I (19 ng/mL) levels returned to normal. This is an example of the usefulness of new cardiooncology units that allow cancer patients to be evaluated, diagnosed and treated early in order to avoid cardiotoxicity and the resulting mortality.
Downloads
References
Hameau R, Gabrielli L, Garrido M, Guzman AM, Retamal I, Vacarezza MJ, et al. Cardiotoxicidad inducida por tratamientos oncológicos. Fundamentos para la implementación de equipos de Cardio-Oncología. Rev Med Chile 2018; 146:68-77.
Force T, Kolaja KL. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov 2011; 10:111-126.
T. Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, et al Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin 2016; 66:309‐325.
Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA. Daunomycin, an antitumor antibiotic, in the treatment of Neoplastic Disease Clinical Evaluation with Special Reference to Childhood Leukemia. Cancer 1967; 20 (3):333-353.
Cardinale D. A new frontier: cardio-oncology. Cardiologia 1996; 41(9):887-891.
López-Fernández T, García AM, Beltrán A, Montero A, García R, Mazón P, et al. Cario-Onco-Hematología en la práctica clínica. Documento de consenso y recomendaciones. Rev Esp Cardiol 2017; 70(6):474-486.
Smith L, Cornelius V, Plummer C. Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010, 10:337.
Morales-Yera R, Sierra-Pérez L, Triana-Díaz A. Cardiotoxicidad inducida por quimioterapia. CorSalud 2018; 10(1):68-77.
Ruiz-Mori E, Pacheco C. Manual de Cardion Oncología. 1 Ed. Lima: Unigraph; 2018. Capítulo 3, Medicamentos Quimioterápicos y corazón; p. 13-28.
Cárdenas-Cardós R. Mecanismos de cardiotoxicidad de la quimioterapia. GAMO 2009; 8 (3):3-7.
Ruiz.Mori E, Ayala-Bustamante LA, Burgos-Bustamante J. Insuficiencia cardiaca por quimioterapia. Rev Soc Per Med Interna 2016; 29(2):59-64.
Yeh E, Ewer M, Moslehi J, Dlugosz-Danecka M, Banchs J, Chang H-M et al. Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology. Seminars in Oncology 2019; 46: 397-402.
Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, Yeh ET. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012; 18: 1639-1642.
Cardinale D, Barac A, Torbicki A, Khandheria B, Lenihan D, Minotti G. Cardio-oncological management of patients. Seminars in Oncology 2019; 46: 408-413.
Virizuela JA, García AM, de las Peñas R, Santaballa A, Andrés R, Beato C, et al. SEOM clinical guidelines on cardiovascular toxicity. Clin Transl Oncol 2019; 21(1):94-105.
Lax J, Piñeiro D. Consenso de diagnóstico, prevención y tratamiento de la cardiotoxicidad por tratamiento médico del cáncer. Rev Arg Cardiol 2013; 81(5): 1-64.
Florenzano F, Venegas P. Prevención de la cardiotoxicidad en pacientes que reciben quimioterapia. Rev Med Clin Condes 2012; 23(6):772-781.
Ganame J, Lepori A. Cardiotoxicidad posquimioterapia: la magnitud del problema. Revista CONAREC 2017; 33(138):16-21.
Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013; 34:1102-1111.
Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2017;35:893–911.
Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014;27:911–939.
Zhang KW, Finkelman BS, Gulati G, Narayan HK, Upshaw J, Narayan V, et al. Abnormalities in 3-dimensional left ventricular mechanics with anthracycline chemotherapy are associated with systolic and diastolic dysfunction. J Am Coll Cardiol Img. 2018; 11: 1059–68.
Santoro C, Arpino G, Esposito R, Lembo M, Paciolla I, Cardalesi C, et al. 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility. Eur Heart J Cardiovasc Imaging. 2017; 18: 930–6.
Mousavi N, Tan TC, Ali M, Halpern EF, Wang L, Scherrer-Crosbie M. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50–59 % treated with anthracyclines. Eur Heart J Cardiovasc Imaging. 2015; 16: 977–84.
Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popović ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013; 61: 77-84.
Reborido N, Parma G, Noria S, Schiavone A, Bonelli A, Lluberas R. Strain bidimensional para detección precoz de disfunción sistólica del ventrículo izquierdo inducida por agentes quimioterápicos. Rev Urug Cardiol. 2016; 31: 266-76.
Tajiri K, Aonuma K, Sekine I. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients. Jpn J Clin Oncol. 2017; 47(8): 678–82.
Virani SA, Dent S, Brezden-Masley C, Clarke B, Davis MK, Jassal DS, et al. Canadian Cardiovascular Society guidelines for evaluation and management of cardiovascular complications of cancer therapy. Can J Cardiol. 2016; 32: 831–41.
Nhola L, Villarraga H. Fundamentos de las unidades de cardio-oncología. Rev Esp Cardiol. 2017; 70(7): 583-9.
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
